AbbVie has announced that its Phase III TEMPLE study, which compared atogepant to topiramate for migraine, has met its ...

India's Department of Pharmaceuticals found AbbVie Healthcare India sponsored ₹1.91 crore in international trips for 30 ...

The latest report, Panic Attack Treatment Global Market Report 2025, brings light to the rapid growth of panic attack treatment market in recent years. The market size is expected to surge from $3.04 ...

AbbVie Golden Ticket Comes to a ClosePress release2025-06-18 11:48AbbVie Golden Ticket ceremony at SmiLe Venture Hub.Lund, Sweden – The one-year AbbVie Golden Ticket program has officially concluded – ...

The global dermal fillers and botulinum toxin market is worth USD 6.8 billion in 2025 and is poised to reach USD 9.3 billion by 2035, expanding at a CAGR of 3.2%. This growth is primarily driven by ...

AbbVie, Lilly, Roche and Takeda have demonstrated strong interest in licensing innovator oligonucleotides for CNS indications ...

AbbVie stock danced a wild intraday tango on Tuesday, only to end up flat-footed at the closing bell. The day’s price swing ...

The protein expression market is primarily driven by the increasing prevalence of chronic diseases, which in turn fuels greater demand for biopharmaceuticals, including monoclonal antibodies and ...

AbbVie’s migraine drug Atogepant just cleared a major Phase 3 hurdle, and it’s got Wall Street rubbing its temples—in ...

The global Parkinson's disease drugs market size is projected to reach $10.4 billion by 2031, growing at a CAGR of 6.2% from 2022 to 2031.

A single, oral dose of rimegepant offered superior relief as soon as 2 hours post-dose compared with placebo in patients with ...

During a live event, Neal E. Ready, MD, and participants discussed use of PD-L1 status in non–small cell lung cancer and ...